These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21710840)

  • 1. HER2-targeted therapies: how far we've come--and where we're headed.
    Davidson NE
    Oncology (Williston Park); 2011 Apr; 25(5):425-6. PubMed ID: 21710840
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
    Moulder SL
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S30-40. PubMed ID: 20805063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on ERBB2.
    Benusiglio PR
    Pharmacogenomics; 2008 Jul; 9(7):825-8. PubMed ID: 18597646
    [No Abstract]   [Full Text] [Related]  

  • 4. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
    Yamashita T; Iwata K
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
    [No Abstract]   [Full Text] [Related]  

  • 5. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 6. [Breast cancer].
    Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
    Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Information for patients. HER2: what you need to know.
    Oncology (Williston Park); 2009 Jul; 23(8 Suppl):48a-48b. PubMed ID: 19860043
    [No Abstract]   [Full Text] [Related]  

  • 8. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 9. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2 testing: the patent "genee" is out of the bottle.
    Goldman B
    CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
    [No Abstract]   [Full Text] [Related]  

  • 11. [Herceptin].
    Morginstin T; Shani S; Shemer J
    Harefuah; 2000 Mar; 138(6):459-64. PubMed ID: 10883160
    [No Abstract]   [Full Text] [Related]  

  • 12. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular targeted therapies in breast cancer: where are we now?
    Widakowich C; de Azambuja E; Gil T; Cardoso F; Dinh P; Awada A; Piccart-Gebhart M
    Int J Biochem Cell Biol; 2007; 39(7-8):1375-87. PubMed ID: 17543572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 15. What is the ideal HER2 test for Herceptin therapy?
    Jpn J Clin Oncol; 2000 Apr; 30(4):208-9, 211. PubMed ID: 10830993
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment.
    Kell MR; Power CP
    BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293849
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted therapies in breast cancer: challenging questions from oncology nurses.
    Becze E
    ONS Connect; 2007; 22(8 Suppl):31-2. PubMed ID: 17824554
    [No Abstract]   [Full Text] [Related]  

  • 18. Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working?
    Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):48a-48b. PubMed ID: 19856610
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn.
    Piccart-Gebhart MJ
    Eur J Cancer; 2006 Aug; 42(12):1715-9. PubMed ID: 16806901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 as a target for breast cancer therapy.
    Tagliabue E; Balsari A; Campiglio M; Pupa SM
    Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.